Germany To Tackle Cell And Gene Therapy Funding Barriers
Executive Summary
If approved, new legislation would allow hospitals to apply for funding for ATMPs before marketing authorization.
You may also be interested in...
Market Access Lessons For Cell And Gene Therapies In Germany
Lawyer and industry expert Alexander Natz sets out some important dos and don’ts for securing a successful launch of an advanced therapy in Germany.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.